A new nomogram to predict pathologic outcome following radical prostatectomy

Detalhes bibliográficos
Autor(a) principal: Crippa,Alexandre
Data de Publicação: 2006
Outros Autores: Srougi,Miguel, Dall’Oglio,Marcos F., Antunes,Alberto A., Leite,Katia R., Nesrallah,Luciano J., Ortiz,Valdemar
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382006000200005
Resumo: OBJECTIVE: To develop a preoperative nomogram to predict pathologic outcome in patients submitted to radical prostatectomy for clinical localized prostate cancer. MATERIALS AND METHODS: Nine hundred and sixty patients with clinical stage T1 and T2 prostate cancer were evaluated following radical prostatectomy, and 898 were included in the study. Following a multivariate analysis, nomograms were developed incorporating serum PSA, biopsy Gleason score, and percentage of positive biopsy cores in order to predict the risks of extraprostatic tumor extension, and seminal vesicle involvement. RESULTS: In univariate analysis there was a significant association between percentage of positive biopsy cores (p < 0.001), serum PSA (p = 0.001) and biopsy Gleason score (p < 0.001) with extraprostatic tumor extension. A similar pathologic outcome was seen among tumors with Gleason score 7, and Gleason score 8 to 10. In multivariate analysis, the 3 preoperative variables showed independent significance to predict tumor extension. This allowed the development of nomogram-1 (using Gleason scores in 3 categories - 2 to 6, 7 and 8 to 10) and nomogram-2 (using Gleason scores in 2 categories - 2 to 6 and 7 to 10) to predict disease extension based on these 3 parameters. In the validation analysis, 87% and 91.1% of the time the nomograms-1 and 2, correctly predicted the probability of a pathological stage to within 10% respectively. CONCLUSION: Incorporating percent of positive biopsy cores to a nomogram that includes preoperative serum PSA and biopsy Gleason score, can accurately predict the presence of extraprostatic disease extension in patients with clinical localized prostate cancer.
id SBU-1_8cc21f485b54e2e72970a65c6f5f5bba
oai_identifier_str oai:scielo:S1677-55382006000200005
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling A new nomogram to predict pathologic outcome following radical prostatectomyprostatic neoplasmsneoplasm stagingnomogramsprostate-specific antigenneedle biopsyOBJECTIVE: To develop a preoperative nomogram to predict pathologic outcome in patients submitted to radical prostatectomy for clinical localized prostate cancer. MATERIALS AND METHODS: Nine hundred and sixty patients with clinical stage T1 and T2 prostate cancer were evaluated following radical prostatectomy, and 898 were included in the study. Following a multivariate analysis, nomograms were developed incorporating serum PSA, biopsy Gleason score, and percentage of positive biopsy cores in order to predict the risks of extraprostatic tumor extension, and seminal vesicle involvement. RESULTS: In univariate analysis there was a significant association between percentage of positive biopsy cores (p < 0.001), serum PSA (p = 0.001) and biopsy Gleason score (p < 0.001) with extraprostatic tumor extension. A similar pathologic outcome was seen among tumors with Gleason score 7, and Gleason score 8 to 10. In multivariate analysis, the 3 preoperative variables showed independent significance to predict tumor extension. This allowed the development of nomogram-1 (using Gleason scores in 3 categories - 2 to 6, 7 and 8 to 10) and nomogram-2 (using Gleason scores in 2 categories - 2 to 6 and 7 to 10) to predict disease extension based on these 3 parameters. In the validation analysis, 87% and 91.1% of the time the nomograms-1 and 2, correctly predicted the probability of a pathological stage to within 10% respectively. CONCLUSION: Incorporating percent of positive biopsy cores to a nomogram that includes preoperative serum PSA and biopsy Gleason score, can accurately predict the presence of extraprostatic disease extension in patients with clinical localized prostate cancer.Sociedade Brasileira de Urologia2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382006000200005International braz j urol v.32 n.2 2006reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-55382006000200005info:eu-repo/semantics/openAccessCrippa,AlexandreSrougi,MiguelDall’Oglio,Marcos F.Antunes,Alberto A.Leite,Katia R.Nesrallah,Luciano J.Ortiz,Valdemareng2006-06-08T00:00:00Zoai:scielo:S1677-55382006000200005Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2006-06-08T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv A new nomogram to predict pathologic outcome following radical prostatectomy
title A new nomogram to predict pathologic outcome following radical prostatectomy
spellingShingle A new nomogram to predict pathologic outcome following radical prostatectomy
Crippa,Alexandre
prostatic neoplasms
neoplasm staging
nomograms
prostate-specific antigen
needle biopsy
title_short A new nomogram to predict pathologic outcome following radical prostatectomy
title_full A new nomogram to predict pathologic outcome following radical prostatectomy
title_fullStr A new nomogram to predict pathologic outcome following radical prostatectomy
title_full_unstemmed A new nomogram to predict pathologic outcome following radical prostatectomy
title_sort A new nomogram to predict pathologic outcome following radical prostatectomy
author Crippa,Alexandre
author_facet Crippa,Alexandre
Srougi,Miguel
Dall’Oglio,Marcos F.
Antunes,Alberto A.
Leite,Katia R.
Nesrallah,Luciano J.
Ortiz,Valdemar
author_role author
author2 Srougi,Miguel
Dall’Oglio,Marcos F.
Antunes,Alberto A.
Leite,Katia R.
Nesrallah,Luciano J.
Ortiz,Valdemar
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Crippa,Alexandre
Srougi,Miguel
Dall’Oglio,Marcos F.
Antunes,Alberto A.
Leite,Katia R.
Nesrallah,Luciano J.
Ortiz,Valdemar
dc.subject.por.fl_str_mv prostatic neoplasms
neoplasm staging
nomograms
prostate-specific antigen
needle biopsy
topic prostatic neoplasms
neoplasm staging
nomograms
prostate-specific antigen
needle biopsy
description OBJECTIVE: To develop a preoperative nomogram to predict pathologic outcome in patients submitted to radical prostatectomy for clinical localized prostate cancer. MATERIALS AND METHODS: Nine hundred and sixty patients with clinical stage T1 and T2 prostate cancer were evaluated following radical prostatectomy, and 898 were included in the study. Following a multivariate analysis, nomograms were developed incorporating serum PSA, biopsy Gleason score, and percentage of positive biopsy cores in order to predict the risks of extraprostatic tumor extension, and seminal vesicle involvement. RESULTS: In univariate analysis there was a significant association between percentage of positive biopsy cores (p < 0.001), serum PSA (p = 0.001) and biopsy Gleason score (p < 0.001) with extraprostatic tumor extension. A similar pathologic outcome was seen among tumors with Gleason score 7, and Gleason score 8 to 10. In multivariate analysis, the 3 preoperative variables showed independent significance to predict tumor extension. This allowed the development of nomogram-1 (using Gleason scores in 3 categories - 2 to 6, 7 and 8 to 10) and nomogram-2 (using Gleason scores in 2 categories - 2 to 6 and 7 to 10) to predict disease extension based on these 3 parameters. In the validation analysis, 87% and 91.1% of the time the nomograms-1 and 2, correctly predicted the probability of a pathological stage to within 10% respectively. CONCLUSION: Incorporating percent of positive biopsy cores to a nomogram that includes preoperative serum PSA and biopsy Gleason score, can accurately predict the presence of extraprostatic disease extension in patients with clinical localized prostate cancer.
publishDate 2006
dc.date.none.fl_str_mv 2006-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382006000200005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382006000200005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1677-55382006000200005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.32 n.2 2006
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318069747548160